SCHEMBL3787591

SCHEMBL3787591

CC(C)(C)c1c(N)cccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
TSHR P16473 5/20 0.48
NR4A2 P43354 3/20 0.46
CYP3A4 P08684 5/20 0.44
PIK3CA P42336 1/20 0.44
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2A6 P11509 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
KEAP1 Q14145 1/20 0.34
CD44 P16070 1/20 0.34
HTR5A P47898 3/20 0.33
HTR1A P08908 2/20 0.33
HTR1D P28221 2/20 0.33
HTR2C P28335 2/20 0.33
HTR7 P34969 2/20 0.33
ALOX15 P16050 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7764379 0.85 ALDH1A1 (0.47) ALDH1A1TSHRNR4A2CYP3A4PIK3CA
SCHEMBL78160 0.83 CYP1A2 (0.43) ALDH1A1TSHRCYP3A4CYP1A2CYP2A6
SCHEMBL9253214 0.83 CYP3A4 (0.48) ALDH1A1TSHRNR4A2CYP3A4PIK3CA
SCHEMBL5116215 0.83 ALDH1A1 (0.48) ALDH1A1TSHRNR4A2CYP3A4PIK3CA
SCHEMBL7753488 0.83 ALDH1A1 (0.48) ALDH1A1TSHRNR4A2CYP3A4PIK3CA
SCHEMBL30233483 0.77 TSHR (0.48) ALDH1A1TSHRNR4A2CYP3A4PIK3CA
SCHEMBL3786889 0.77 TSHR (0.48) ALDH1A1TSHRNR4A2CYP3A4PIK3CA
Hydrochloric Acid SCHEMBL4725830 0.76 TSHR (0.46) ALDH1A1TSHRNR4A2CYP3A4PIK3CA
SCHEMBL803041 0.74 GABRA1 (0.40) ALDH1A1TSHRCYP1A2CYP2A6HTR2C
SCHEMBL9607578 0.74 CD44 (0.52) ALDH1A1TSHRCYP3A4PIK3CAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210002233-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE SUMITOMO PHARMA ONCOLOGY, INC. 2021-01-07 US disclosed
US-20200237766-A1 PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER SUMITOMO PHARMA ONCOLOGY, INC. 2020-07-30 US disclosed
US-10472328-B2 PKM2 modulators and methods for their use TOLERO PHARMACEUTICALS, INC. (US) 2019-11-12 US disclosed
US-20190119219-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE SUMITOMO PHARMA ONCOLOGY, INC. 2019-04-25 US disclosed
US-20170015631-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE SUMITOMO PHARMA ONCOLOGY, INC. 2017-01-19 US disclosed
US-20170015631-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE SUMITOMO PHARMA ONCOLOGY, INC. 2017-01-19 US disclosed
US-9394257-B2 PKM2 modulators and methods for their use TOLERO PHARMACEUTICALS, INC. (US) 2016-07-19 US disclosed
US-20150344436-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE SUMITOMO PHARMA ONCOLOGY, INC. 2015-12-03 US disclosed
US-20120135975-A1 Substituted Esters as Cannabinoid-1 Receptor Modulators MERCK & CO., INC. (US) 2012-05-31 US disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 ALDH1A1 4339/4885TSHR 1688/4885NR4A2 888/4885
US-10472328-B2 PKM2 modulators and methods for their use PDK1, PDK2, PKM ALDH1A1 2333/4885TSHR 249/4885NR4A2 1506/4885
US-20170015631-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE PDK1, PDK2, PKM ALDH1A1 2333/4885TSHR 249/4885NR4A2 1506/4885
US-20120135975-A1 Substituted Esters as Cannabinoid-1 Receptor Modulators CNR1, CNR2, FAAH ALDH1A1 2986/4885TSHR 768/4885NR4A2 1027/4885
US-20200237766-A1 PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER PDK1, PDK2, PCK2 ALDH1A1 978/4885TSHR 1094/4885NR4A2 2841/4885
US-20190119219-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE PDK1, PDK2, PKM ALDH1A1 2333/4885TSHR 249/4885NR4A2 1506/4885
US-20210002233-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE PDK1, PDK2, PKM ALDH1A1 2333/4885TSHR 249/4885NR4A2 1506/4885
US-20150344436-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE PDK1, PDK2, PKM ALDH1A1 2333/4885TSHR 249/4885NR4A2 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.